EGUVF
Evergreen Corporation does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Kuala Lumpur, Malaysia.
EGUVF (EGUVF) - Net Assets
Latest net assets as of February 2025: $15.04 Million USD
Based on the latest financial reports, EGUVF (EGUVF) has net assets worth $15.04 Million USD as of February 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($26.73 Million) and total liabilities ($11.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.04 Million |
| % of Total Assets | 56.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3.18 |
EGUVF - Net Assets Trend (2021–2024)
This chart illustrates how EGUVF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for EGUVF (2021–2024)
The table below shows the annual net assets of EGUVF from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-11-30 | $44.44 Million | -40.78% |
| 2023-11-30 | $75.03 Million | -34.42% |
| 2022-11-30 | $114.42 Million | +2354386.23% |
| 2021-11-30 | $-4.86K | -- |
Equity Component Analysis
This analysis shows how different components contribute to EGUVF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1096985300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (November 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $55.41 Million | 124.70% |
| Total Equity | $44.44 Million | 100.00% |
EGUVF Competitors by Market Cap
The table below lists competitors of EGUVF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SHIMAO PPTY
MU:QHI
|
$271.88 |
|
Dundas Minerals Ltd
AU:DUN
|
$272.10 |
|
Ashoka India Equity Investment Trust PLC
LSE:AIE
|
$273.04 |
|
Alteration Earth PLC
LSE:ALTE
|
$273.76 |
|
Healixa Inc
PINK:EMOR
|
$271.29 |
|
Universal Media Group Inc
PINK:UMGP
|
$271.05 |
|
Fashion Bel Air S.A
PA:ALFBA
|
$270.95 |
|
HH Biotechnology Holdings Company
PINK:HHBT
|
$270.33 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EGUVF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 75,033,200 to 44,437,768, a change of -30,595,432 (-40.8%).
- Net income of 1,768,961 contributed positively to equity growth.
- Share repurchases of 32,364,394 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.77 Million | +3.98% |
| Share Repurchases | $32.36 Million | -72.83% |
| Other Changes | $1.00 | +0.0% |
| Total Change | $- | -40.78% |
Book Value vs Market Value Analysis
This analysis compares EGUVF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-11-30 | $0.00 | $0.03 | x |
| 2022-11-30 | $7.68 | $0.03 | x |
| 2023-11-30 | $6.88 | $0.03 | x |
| 2024-11-30 | $5.51 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EGUVF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.25x
- Recent ROE (3.98%) is above the historical average (3.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.79% | 0.00% | 0.00x | 1.04x | $-10.54 Million |
| 2023 | 4.90% | 0.00% | 0.00x | 1.11x | $-3.83 Million |
| 2024 | 3.98% | 0.00% | 0.00x | 1.25x | $-2.67 Million |
Industry Comparison
This section compares EGUVF's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EGUVF (EGUVF) | $15.04 Million | 0.79% | 0.78x | $271.44 |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |